All Search Results
-
Orlando Health Jewett Orthopedic Institute Hand Surgeon Invents New Splint for Better Patient Outcomes
Orlando, FL (February 26, 2026) – Orlando Health has launched a pilot study of a new splint, invented by one of its own physicians, to improve patient care following a hand or wrist injury. Jeffrey Deren, MD has been practicing medicine for 30 years and saw an opportunity to enhance patient experience and outcomes with the invention of “SafeSplint.” The splint is currently being trialed at several Orlando Health emergency departments and the Orlando Health Jewett Orthopedic Institute – Alafaya/Waterford Lakes walk-in clinic before systemwide and nationwide distribution.
-
Orlando Health – Health Central Hospital expands patient care with new cardiac catheterization lab
Orlando, FL (April 15, 2026) – Orlando Health – Health Central Hospital has opened a new cardiac catheterization lab, expanding access to advanced electrophysiology and arrhythmia care at the Ocoee-based hospital. Hospital leaders, physicians and team members gathered this week to celebrate the state-of-the-art space with a ribbon-cutting ceremony.
-
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of
-
Orlando Health launches robotic cardiac surgery program, brings new treatment options to patients
Orlando, Fla. (February 21, 2023) – Cardiovascular surgeons at Orlando Health Heart and Vascular Institute are scrubbing in for heart surgery with robotic assisted technology. The robotic cardiac surgery program is currently the only program of its kind in Orlando, providing robotic-assisted surgery for structural and valve disease.
-
New Procedure May Reduce Lifetime Stroke Risk in A-Fib Patients
Stroke is the fifth leading cause of death in the country, and every year 795,000 Americans experience this condition.
-
Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
-
Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
-
ORMC’s Air Care Team soars to new heights, transports 28,000th patient
Learn about the Air Care Team’s 30 years of impressive service.
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
AAML1831 - A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
-
ORMC Has New Address
Orlando Health ORMC and Emergency Department now have new physical addresses to help direct patients and visitors using online maps and GPS.
